Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2015-09-01 |
Intellia Therapeutics (USA - MA) |
$70 Million |
series B financing round |
OrbiMed (USA - NY) Fidelity Biosciences (USA - MA) Management and Research Company (USA - CA) Janus Capital Management (USA - CO) Foresite Capital (USA - NY) Sectoral Asset Management (Canada) EcoR1 Capital (USA - CA) Atlas Venture (USA - MA) Novartis (Switzerland) |
|
Series B financing round |
2015-08-25 |
Reneuron (UK) |
£68.4 million (€ 93 million) |
private placement |
new and existing investors including Woodford Investment Management (UK) |
Regenerative Medicine |
Private placement |
2015-08-24 |
TRUST project ( Txcell (France) Provepep (France) University Hospital La Pitié Salpêtrière (France) Quinze-Vingts Hospital Center of ophthalmology (France) |
€ 1.28 million |
grant |
FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France) |
Autoimmune diseases - Inflammatory diseases - Ophtalmological diseases |
Grant |
2015-08-22 |
Helix (USA - CA) |
$ 100 million |
financing round |
Illumina (USA - CA) Warburg Pincus (USA - CA) Sutter Hill Ventures (USA - CA) Mayo Clinic (USA - MN) |
Technology - Services |
Financing round |
2015-08-19 |
Telesta Therapeutics (Canada) |
$28.6 million |
private placement |
Consonance Capital Investors (USA - NY) Boxer Capital of Tavistock Life Sciences (Bahamas) Omega Funds (USA - MA) members of the senior management team and board of directors of Telesta |
Cancer - Oncology |
Private placement |
2015-08-19 |
Orbus Therapeutics (USA - CA) |
$32.5 million |
series A financing round |
Longitude Capital, H.I.G. BioVentures Adams Street Partners. Dr. Ernest Mario |
|
Series A financing round |
2015-08-19 |
Orbus Therapeutics (USA - CA) |
$32.5 million |
series A financing round |
Longitude Capital (USA - CA) H.I.G. BioVentures (USA) Adams Street Partners (USA) Dr. Ernest Mario |
Cancer - Oncology - Rare diseases |
Series A financing round |
2015-08-18 |
Medicinova (USA - CA) |
|
private placement |
|
|
Private placement |
2015-08-12 |
Checkmate Pharmaceuticals (USA - MA) |
$ 20 million |
series A financing round |
Sofinnova Ventures (USA - CA) venBio (USA - CA) |
Cancer - Oncology |
Series A financing round |
2015-08-07 |
Santhera Pharmaceuticals (Switzerland) |
CHF 27.7 Million (€ 25.8 million) |
private placement |
|
Rare diseases - Genetic diseases - Neuromuscular diseases - Ophtalmological diseases |
Private placement |
2015-08-05 |
Amag Pharmaceuticals (USA - MA) |
$231 Million (€ 212.1 million) |
private placement |
|
|
Private placement |
2015-08-04 |
Biophytis (France) |
€6 million |
capital increase |
undisclosed US investor |
Metabolic diseases - Neurodegenerative diseases - Ophtalmological diseases |
Capital increase |
2015-07-31 |
Kiadis Pharma (The Netherlands) |
€ 34.7 million |
IPO |
|
Cancer - Oncology |
IPO |
2015-07-29 |
Mereo BioPharma (UK) |
$118 million (£76.5 million - € 106.6 million) |
series A financing round |
Woodford Investment Management (UK) Invesco Perpetual (UK) Novartis (Switzerland) |
Rare diseases |
Series A financing round |
2015-07-28 |
Pieris (Germany) |
$28.3 million |
IPO |
|
|
IPO |
2015-07-28 |
Erytech Pharma |
|
IPO |
|
Cancer - Oncology - Rare diseases |
IPO |
2015-07-24 |
Poxel (France) |
€ 20 million |
capital increase |
|
Metabolic diseases |
Capital increase |
2015-07-23 |
Exelixis (USA - CA) |
$135 million |
private placement |
|
Cancer - Oncology |
Private placement |
2015-07-22 |
KalVista Pharmaceuticals (UK) |
$33 million |
series B financing round |
Novo A/S (Denmark) RA Capital Management (USA - MA) SV Life Sciences (UK - USA) Longwood Fund (USA) Venrock (USA - CA) |
|
Series B financing round |
2015-07-22 |
Txcell (France) |
€ 8 million |
private placement |
|
Autoimmune diseases – Inflammatory diseases - Digestive diseases - Ophtalmological diseases |
Private placement |